Javier Sosa Faria
Juana Diaz, PRNPI 1205911203
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,310 of the $1,557 with a category attached, or 84.2%. Endo USA, Inc. accounts for 96.2% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $1,498, more than ten times the $13 reported in 2021.
Across 10 payments — averaging $155.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo USA, Inc.$1K
- Smith+Nephew$59
Across 41 payments — averaging $11,509 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly Export S.A. Puerto Rico Branch$323K
- Convatec Inc.$80K
- E.r. Squibb & Sons, L.L.C.$19K
- AstraZeneca$18K
- Janssen Research & Development, LLC$14K
- Eli Lilly$10K
- plus $8K from 3 others
What the payments were for
- Travel & lodging$1,31084%
- Food & beverage$24616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo USA, Inc. | 7 | $1,498 |
| Smith+Nephew | 3 | $59 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 27 | $8,268 |
| Ciprofloxacin Hcl | 38 | $422 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $404 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 62 | $346 |
| Clindamycin Hcl | 15 | $281 |
| Tramadol Hcl | 14 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $59 | $8,26827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.